AirSculpt Technologies, Inc. is a holding company that operates a network of body contouring centers in the United States and Canada. The company provides minimally invasive fat removal and skin tightening procedures using its proprietary AirSculpt® method, which utilizes a patented corkscrew motion to remove fat cells without needles, scalpels, or general anesthesia. Its service portfolio includes the AirSculpt® + treatment, which combines helium gas and radiofrequency energy for skin tightening, and AirSculpt® Smooth for cellulite reduction. The company also offers fat transfer procedures such as the Power BBL®, Up a Cup™ breast enhancement, Hip Flip™ hourglass contouring, and facial or hand rejuvenation using the patient's own fat cells. Operations are conducted through surgeon-owned Professional Associations that manage clinical aspects, while wholly-owned subsidiaries handle non-clinical assets and management services. The company serves patients through 31 centers located in metropolitan and suburban areas across 20 U.S. states and Canada.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Care Facilities Homepage airsculpt.com
Sector Healthcare IR page investors.elitebodysculpture.com
Tags
body contouring, fat removal, skin tightening, fat transfer, minimally invasive surgery, aesthetic medicine, cellulite reduction, plastic surgery, AirSculpt®, AirSculpt® +, AirSculpt® Smooth, Power BBL®, Up a Cup™, Hip Flip™, AirSculpt® Lift, AirSculpt® TV
Press page airsculpt.com/news

Metrics

Valuation  
Market cap $ 57.344M
Market cap (USD) $ 57.344M
P/E -5.97
PEG —
P/BV 0.54
P/S 0.39
P/OCF -29.06
P/FCF -22.61
Dividend yield 15.5%
Turnover / mcap —
Returns  
ROE -14.0%
ROI -8.1%
ROIC -6.0%
Profit margin -7.7%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 34.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 8
Quality score -55.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 151.818M 180.35M 195.917M 168.794M 133.315M 62.766M
Net profit -11.667M -8.251M -4.479M -14.679M 10.551M 7.577M
Free cash flow 692K -2.657M 14.037M 11.526M 19.517M 10.268M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 1.98 5.19 7.49 3.7 17.19 —
Price performance 12m -0.62 -0.31 1.02 -0.78 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — 400,000 850,000 2.13M 2.13M 4.25M 5.46M
Borrowings, non-current (USD) — — 32.1M 81.8M 81.4M 69.5M 65.5M 50.6M
Lease liabilities (USD) — — 17.2M 18M 24.1M 28M 30.3M 27.5M
Cash and deposits (USD) 5.41M 5.13M 10.4M 25.3M 9.62M 10.3M 8.24M 8.45M
Intangible assets (USD) — — 60.6M 55.9M 51.1M 46.3M 41.6M 36.8M
Right-of-use assets (USD) — — 17.1M 18.2M 23.8M 25.4M 25.7M 22.5M
Net debt (borrowings + leases - cash) (USD) — — 39.4M 75.2M 98M 89.4M 91.8M 75.1M
Cash flow detail
Operating cash flow (USD) — 4.94M 14M 26.6M 24.4M 24M 11.4M 3.1M
Purchases of property, plant and equipment (USD) — -4.44M -3.69M -7.12M -12.9M -9.92M -14M -2.4M
Change in payables (cash effect) (USD) — 1.87M -1.02M 1.58M 865,000 -206,000 739,000 579,000
Dividends paid (cash effect) (USD) — — 0.00 0.00 -23.2M -385,000 -252,000 0.00
Interest paid (cash effect) (USD) — -2.68M -2.29M -4.26M -5.83M -6.28M -6M -5.56M
Income taxes paid (cash effect) (USD) — — 0.00 0.00 -4.93M -4.66M -1.81M -1.83M
Share-based compensation (USD) — 341,000 325,000 7.19M 29.5M 18.2M 3.76M 2.33M
Free cash flow (OCF - PPE - intangibles) (USD) — 499,000 10.3M 19.5M 11.5M 14M -2.66M 692,000
Income detail
Total comprehensive income (USD) — — 7.58M 10.6M -14.8M -4.82M -8.53M -11.1M
Comprehensive income to owners (USD) — — 7.58M 10.6M -14.8M -4.82M -8.53M -11.1M
Reported Mar 11, 2022 Mar 11, 2022 Mar 10, 2023 Mar 10, 2023 Mar 10, 2023 Feb 27, 2024 Mar 14, 2025 Mar 31, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Completes Term Loan Refinancing, Extending Maturity to 2031

TAMPA, Fla., November 6, 2026 (GLOBE NEWSWIRE) – AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the third quarter ended September 30, 2026.

Yogi Jashnani, Chief Executive Officer, stated: "While our third quarter results were below expectations, we identified the key drivers and are addressing them with a sense of urgency. Importantly the quarter saw strong progress on our priorities, including expanding our GLP-1-related procedures. Following quarter end, we marked a key milestone as we completed the refinance of our term loan - extending our debt maturity to 2031.

Completes Term Loan Refinancing, Extending Maturity to 2031

TAMPA, Fla., November 6, 2026 (GLOBE NEWSWIRE) – AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the third quarter ended September 30, 2026.

Yogi Jashnani, Chief Executive Officer, stated: "While our third quarter results were below expectations, we identified the key drivers and are addressing them with a sense of urgency. Importantly the quarter saw strong progress on our priorities, including expanding our GLP-1-related procedures. Following quarter end, we marked a key milestone as we completed the refinance of our term loan - extending our debt maturity to 2031.

Airsculpt Partners With Tiger Aesthetics to Offer alloClae Bull 2 Bear 0 Product/operations

Airsculpt Logo

vcRequest Consultation

Book Consultation
[Phonewhite phone](tel:(866) 600-7202/)

Exclusive Event

The Gift of Body Confidence

November 12, 2026

Reserve Your Spot

Jessica Woolridge

2026-08-12

facebooktwitterpinterest

Airsculpt Partners With Tiger Aesthetics in First National Partnership to Offer alloClae

Further expanding AirSculpt's body enhancement offerings, the partnership brings alloClae™ to patients nationwide.

MIAMI BEACH, Fla., Aug. 12, 2026 -- AirSculpt®, the leader in minimally invasive body contouring, today announced the first national partnership with Tiger Aesthetics™ for alloClae™, an off-the-shelf structural adipose tissue designed for aesthetic body procedures. Launching in August across select AirSculpt locations, the rollout reflects AirSculpt's commitment to expand availability nationwide by the end of 2026.

The strategic partnership expands AirSculpt's body enhancement offerings by adding alloClae as a new treatment option for patients seeking natural-looking volume restoration and contour refinement—particularly those who may not have sufficient fat for a traditional fat transfer procedure. It may be incorporated into treatment plans for enhancing areas such as the hips, buttocks, breasts, and to improve contour irregularities following liposuction, allowing AirSculpt surgeons another customizable solution to help patients achieve their aesthetic goals through personalized treatment plans.

"At AirSculpt, we're continually evaluating new technologies that complement our expertise and meaningfully expand what's possible for our patients," said Yogi Jashnani, Chief Executive Officer of AirSculpt. "Our partnership with Tiger Aesthetics reflects our commitment to remaining at the forefront of body contouring innovation while giving more patients access to personalized solutions through our national network. We're excited to introduce alloClae as another way to help patients achieve natural-looking results tailored to their individual goals."

As consumer demand for minimally invasive body contouring and body enhancement continues to grow, driven in part by the rise of GLP-1 medications and evolving aesthetic goals, AirSculpt is expanding its treatment portfolio to provide patients with more personalized solutions through its nationwide network.

"With the growing use of weight loss medications and increasing consumer demand for regenerative treatments, alloClae provides a unique, non-surgical option for patients to restore targeted volume in a fully natural way," said Caro Van Hove, President of Tiger Aesthetics. "This partnership is a natural fit that expands access for patients nationwide and enables AirSculpt to help patients who otherwise have very limited options." 

alloClae™ is a structural adipose tissue allograft used for non-surgical body contouring, designed to add subtle, natural-looking, targeted volume - helping restore balance, smooth contours, and enhance a patient's natural shape. Typically performed in-office in under an hour, alloClae™ delivers immediate results with minimal downtime.

As AirSculpt continues to expand its body contouring and enhancement offerings, additional treatment options, treatment areas and clinic availability will be announced nationwide throughout 2026.

About AirSculpt®

AirSculpt® is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt® offices. The minimally invasive procedures can remove fat, tighten skin, and add volume through fat transfers to sculpt targeted areas of the body, allowing for quick healing with minimal bruising, and precise, lasting results.

Media Contact

clover PR
Jessica Woolridge
[email protected]

facebookgoogle plustwitterlinked in

AirSculpt

AirSculpt® is a registered trademark | Elite Body Sculpture is the exclusive provider of AirSculpt®

[white phonephone

Call Now!](tel:(866) 600-7202/)

LOCATIONS

PROCEDURES

Copyright © 2026 AirSculpt® Technologies . All Rights Reserved

We would like to store cookies on your device to enhance site functionality, analyze site usage, and assist in our marketing efforts. Please use the buttons below to accept or reject all optional cookies, or click “Cookie Settings” to customize the purposes for which we may store these cookies.View our Privacy Policy

Cookie Settings

Reject Optional Cookies Allow All Cookies

Company Logo

Privacy Preferences

This site uses cookies and similar tools, some of which are provided by third parties, to operate and improve our site, enable social media and other features, support our advertising and marketing, collect user data, IP address and online identifiers, referring URLs and other browsing information, and record user sessions. We and these third parties use this information to analyze and improve performance and usage, understand more about users, provide personalized experiences, and reach users with more relevant content and ads on this site and third-party sites. For more information, please see our privacy policy.
View our Privacy Policy

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to your actions which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms. You can set your browser to block or alert you about these cookies, but then, some parts of the site will not work.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is provided to us in an aggregated, anonymous format. If you do not allow these cookies, we will not know when you have visited our site and will not be able to monitor its performance.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. Those companies may use the cookies to build a profile of your interests and show you relevant adverts on other sites. If you do not allow these cookies, you will experience less targeted advertising.

Back Button

Cookie List

Search Icon

Filter Icon

Clear

checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject Optional Cookies Confirm My Choices

Powered by Onetrust

Prompts

AirSculpt Technologies, Inc. (ticker AIRS), listed in United States.

ETFs Holding AirSculpt Technologies, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 1,733 $ 1,213.10 Nov 16, 2026